Mustang Bio, Inc.: Business Overview, Financials & Competitive Analysis
Mustang Bio, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Early-stage cell therapy platform with legitimate science and partnerships but severe capital constraints and competitive headwinds limit near-term value creation. Since August 2017, Mustang Bio's market cap has decreased from $257.00M to $5.77M, a decrease of 97.75%. The company is pre-revenue and operating with limited capital resources in a.
What is Mustang Bio, Inc.'s industry? Mustang Bio, Inc. (mustangbio.com) operates in Gene Therapy. AskCyborg classifies Mustang Bio, Inc. under Gene Therapy in its company registry.
Mustang Bio is a clinical-stage biopharmaceutical company focused on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company has partnered with to...
Cyborg Score thesis
Early-stage cell therapy platform with legitimate science and partnerships but severe capital constraints and competitive...
Read the full analyst-debate transcript →Get the Latest Mustang Bio, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMustang Bio, Inc. Overview
Pro stress-test →Mustang Bio is a clinical-stage biopharmaceutical company focused on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company has partnered with top medical institutions to advance the development of CAR-T therapies, with MB-106 as its lead clinical candidate.
Strategic Profile
Pro stress-test →Mustang was founded by Fortress Biotech, Inc. The company operates a licensing and partnership model, acquiring rights to cell and gene therapy technologies and advancing them through clinical development. As of June 2, 2026, Mustang Bio has a market capitalization of $5.77 million, reflecting significant shareholder dilution from its peak, though the company continues advancing multiple clinical programs.
Competitive Landscape
Pro stress-test →Mustang competes in the cell therapy/CAR-T space against better-capitalized public companies including Gilead Sciences (CAR-T leader), Novartis, Juno Therapeutics/Celgene, and numerous private cell therapy developers. Mustang's clinical-stage status and limited resources place it at a disadvantage relative to established CAR-T manufacturers and larger biotech competitors with proven manufacturing and commercial capabilities.
Industry Context
Mustang Bio, Inc. operates in Gene Therapy.
Key facts
Founded: 2015 · Headquarters: Worcester, US · Employees: N/A · Revenue: N/A · Market cap: $5.77M